# Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

> **NCT00230334** · PHASE2 · TERMINATED · sponsor: **Steven E. Coutre** · enrollment: 5 (actual)

## Conditions studied

- Eosinophilia
- Hypereosinophilic Syndrome

## Interventions

- **DRUG:** Gleevec

## Key facts

- **NCT ID:** NCT00230334
- **Lead sponsor:** Steven E. Coutre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-06-12
- **Primary completion:** 2006-12-29
- **Final completion:** 2007-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** terminated by PI due to insufficient accrual
- **Last updated:** 2021-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00230334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00230334, "Phase II Gleevec Idiopathic Hypereosinophilic Syndrome". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00230334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*